Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from SynAct Pharma AB ( (SE:SYNACT) ).
SynAct Pharma AB released its interim report for the third quarter of 2025, highlighting significant events and financial developments. The report underscores the company’s ongoing research and development efforts in inflammatory diseases, which are crucial for its market positioning and stakeholder interests.
More about SynAct Pharma AB
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation through melanocortin biology.
Average Trading Volume: 179,014
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.14B
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.